Neurocrine Biosciences, Inc.(NBIX)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
NBIX | 14.43 B | 20.82x | 39.50% | 20.91% | $6.82 | 22.09% | 0.13x | 0.00% | $186.12 | $122.14 |
MRNA | 96.65 B | - | 2.10% | -141.43% | -$7.98 | -39.00% | 0.19x | 0.00% | $243.98 | $22.28 |
UTHR | 23.76 B | 19.86x | -1.90% | 41.56% | $27.89 | 19.32% | - | 0.00% | $609.35 | $409.07 |
INCY | 23.64 B | 14.86x | 37.70% | 27.71% | $7.85 | 30.67% | 0.01x | 0.00% | $132.60 | $84.02 |
INSM | 20.89 B | - | 296.10% | -76.94% | -$4.10 | -87.22% | 0.98x | 0.00% | $212.75 | $90.39 |
Peer Valuation & Performance Analysis
Peer group analysis for Neurocrine Biosciences, Inc. (NBIX) compared to its primary competitors (including MRNA, UTHR, INCY) reveals distinct metrics. NBIX trades at a valuation premium compared to its competitors, with a P/E ratio of 20.8x versus the peer average of -4.7x (representing a -539% premium). This indicates that the market expects superior growth or commands a quality premium for NBIX. In terms of growth, NBIX's revenue growth of 39.5% lags behind the peer average of 83.5%, indicating potential market share losses or slower industry adoption. Additionally, it boasts superior profitability with a net margin of 20.9% compared to the peer average of -37.3%, demonstrating strong cost controls and pricing power.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• NBIX ranks #3 in P/E ratio, #2 in revenue growth, and #3 in profit margins
• Average ranking: #3 - 📊 Solid financials relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-20 | $138.51 | $142.09 | $137.90 | $142.00 | 1,252,508 | +3.66% |
| 2026-10-19 | $136.34 | $137.53 | $135.01 | $136.98 | 1,050,400 | +0.94% |
| 2026-10-16 | $137.86 | $138.20 | $135.55 | $135.71 | 1,127,400 | -0.91% |
| 2026-10-15 | $137.26 | $138.23 | $135.55 | $136.95 | 1,379,100 | +0.77% |
| 2026-10-14 | $133.94 | $136.57 | $132.25 | $135.91 | 1,506,700 | +0.58% |
| 2026-10-13 | $139.60 | $139.93 | $134.89 | $135.13 | 1,568,300 | -4.41% |
| 2026-10-12 | $142.37 | $143.63 | $140.89 | $141.37 | 1,092,100 | -0.75% |
| 2026-10-09 | $141.33 | $143.55 | $140.02 | $142.44 | 1,019,500 | +0.84% |
| 2026-10-08 | $142.88 | $143.02 | $140.34 | $141.25 | 1,237,200 | -1.55% |
| 2026-10-07 | $145.33 | $145.88 | $143.21 | $143.47 | 1,143,700 | -1.40% |
| 2026-10-06 | $145.56 | $145.77 | $141.39 | $145.51 | 1,449,500 | +0.90% |
| 2026-10-05 | $142.94 | $146.92 | $142.48 | $144.21 | 1,748,200 | +0.72% |
| 2026-10-02 | $141.41 | $144.56 | $140.36 | $143.18 | 1,648,200 | +1.76% |
| 2026-10-01 | $140.94 | $143.74 | $139.61 | $140.71 | 2,052,000 | -0.80% |
| 2026-09-30 | $138.33 | $142.91 | $137.63 | $141.84 | 1,847,000 | +2.52% |
Explore More Analysis for NBIX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.